Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
American Cancer Society Cancer Action Network, Inc.

2. Address

Address1
655 15th St, NW
 Address2
​Suite 503
City
WASHINGTON
 State
DC
 Zip Code
20005
 Country
USA

3. Principal place of business (if different than line 2)

City
​
State
​
Zip Code
​
Country
​
4a. Contact Name b. Telephone Number c. E-mail
​Ms.
​Stephanie Krenrich
​2029982802
​stephanie.krenrich@cancer.org
5. Senate ID#
​288670-12
7. Client Name Self Check if client is a state or local government or instrumentality
​American Cancer Society Cancer Action Network, Inc.
6. House ID#
​371000000
TYPE OF REPORT 8. Year
​2022
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​
$5,000 or more $
​730,000.00
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: Rosalie Abbott
 Date
4/20/2022 10:32:47 AM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, cannabis research, and wellness, including:

The Build Back Better Act, HR 5376 & budget reconciliation discussions

HR 1550, The Prevent HPV Cancers Act 

S 464/HR 2163 Safe Step Act

S. 699, Women and Lung Cancer Research and Preventive Services Act of 2021

HR 623, Gabriella Miller Kids First Research Act 2.0

The Palliative Care and Hospice Education and Training Act (soon to be introduced)

Provider Training in Palliative Care Act, S 2890

Issues related to the proposed HELP workforce proposal.

Issues related to the possible introduction of the 21st Century Cures Act version 2.0

Regulations implementing the No Suprises Act

OMB RFI on health equity - comments

ACA subsidies expansion permanency - next legislative package

Advocacy around subpar health plans - next legislative package

DICT RFI - Eshoo

DICT Ancillary Costs legislation/Menendez, Scott, Smith, Young, Ruiz

House/Senate Appropriations Committee FDA DICT report language

Reducing Hereditary Cancer Act of 2021 - DWS, Slotkin, Miller-Meeks, and Davis

Personal Care Products Safety Act - Feinstein, Collins

H.R. 6638 - Reducing COVID-19 Disparities by Investing in Public Health Act of 2021

The VALID Act - DeGette, Bennet, Burr, Buschon

DIVERSE Trials Act - H.R.5030/ S.2706

DEPICT Act

Give Kids a Chance Act, H.R. 6972

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Food & Drug Administration (FDA), White House Office, Natl Institutes of Health (NIH), U.S. Agency for International Development (USAID), Environmental Protection Agency (EPA), Office of Management & Budget (OMB), State - Dept of (DOS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Stephanie
Krenrich
​
​
Illy
Jaffer
​
​
Rosalie
Abbott
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations.

Issues related to stimulus for nonprofit organizations and increasing charitable giving.

Legacy IRA Act, S, 243

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Treasury - Dept of, Small Business Administration (SBA), Federal Reserve System

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Stephanie
Krenrich
​
​
Illy
Jaffer
​
​
Rosalie
Abbott
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TOB

16. Specific lobbying issues

Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments, including:

Implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation;

Issues relating to FDA regulation of menthol, flavors, electronic cigarettes and cigars;

HR 2125, The Quit Because of COVID-19 Act 

S.2622, The Quit Because of COVID-19 Act

HR 2786/S 1314 - Tobacco Tax Equity Act of 2021

The PROTECT Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Stephanie
Krenrich
​
​
Illy
Jaffer
​
​
Rosalie
Abbott
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

FY 2022 federal appropriations for cancer research and prevention funding at the NIH, NCI and CDC; emergency funding to restart COVID-19 impacted cancer research and clinical trials at the NIH; policy issues and funding related to the CDCs and FDAs tobacco work; issues and funding related to non-communicable diseases; ; issues related to highway authorization and appropriations, and issues related to funding of domestic medical isotope molybdenum-99 (Mo-99) program at the Department of Energy (DOE).

HR 869/S. 289 RISE Act of 2021

S.962 - A bill to prioritize funding for an expanded and sustained national investment in biomedical research.

Issues related to appropriations for consumer assistance programs, under the Labor, Health and Human Services appropriations bill.

HR 2786/S. 1314 - Tobacco Tax Equity Act of 2021

Cures 2.0 RFI - DeGette, Upton

ARPA-H Principles

FY22 Omnibus - NIH, NCI, CDC DCPC and OSH funding requests

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Disease Control & Prevention (CDC), State - Dept of (DOS), Natl Institutes of Health (NIH), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA), Defense - Dept of (DOD), U.S. Agency for International Development (USAID), Transportation - Dept of (DOT)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Stephanie
Krenrich
​
​
Illy
Jaffer
​
​
Rosalie
Abbott
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including:

The Build Back Better Act, HR 5376 & budget reconciliation discussions

HR 1946, Multi Cancer Early Detection Screening Coverage Act

HR 2594, To amend title XVIII of the Social Security Act to eliminate the coinsurance requirement for certain colorectal cancer screening tests furnished under the Medicare program.

S. 245, SAME Act of 2021

HR 340, the Incentivizing Medicaid Expansion Act

HR 66, the Comprehensive Access to Robust Insurance Now Guaranteed for Kids Act

HR 1791, the Childrens Health Insurance Permanency Act

Issues related to governance of state Medicaid programs, including work requirements and block grant proposals.

Issues related to the waiting period for SSDI and Medicare.

Home and Community Based Services Access Act

Policy issues related to coverage for low-income populations in states that have not yet expanded their Medicaid programs (coverage gap)

Cancer Care Planning and Communications Act, HR 4414

CONNECT Act (telehealth), S. 1512

Lymphedema Treatment Act, HR 3630, S. 1315

Bipartisan Seniors Prescription Drug Relief Act - Cassidy/Menendez

Expanding Access to Affordable Prescription Drugs and Medical Devices Act - Rosen

Accelerating Kids Access to Care Act, S. 1544/H.R. 3089

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Stephanie
Krenrich
​
​
Illy
Jaffer
​
​
Rosalie
Abbott
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​
​
​
3
​
​
​
2
​
​
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)